Virtual Screening Models for Prediction of HIV-1 RT Associated RNase H Inhibition

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Poongavanam, Vasanthanathan ^a   Kongsted, Jacob ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CAPRAVIRINE; EFAVIRENZ; ETRAVIRIDINE; GW 8248; ILLIMAQUINONE; NAPHTHYRIDINE DERIVATIVE; NEVIRAPINE; NSC 727447; PD 126338; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIAZOLE; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; ARTICLE; CHELATION; CHEMICAL DATABASE; CHEMICAL STRUCTURE; COMPUTER MODEL; COMPUTER PROGRAM; DRUG EFFICACY; DRUG IDENTIFICATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; K NEAREST NEIGHBOR; MOLECULAR DOCKING; MOLECULAR INTERACTION; NONHUMAN; PHARMACOPHORE; PROTEIN TARGETING; RANDOM FOREST; STRUCTURE ACTIVITY RELATION; SUPPORT VECTOR MACHINE; VALIDATION PROCESS; VIRTUAL REALITY;

ARTIFICIAL INTELLIGENCE; ENZYME INHIBITORS; HIV REVERSE TRANSCRIPTASE; MODELS, THEORETICAL; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RIBONUCLEASE H;

EID: 84884186947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073478     Document Type: Article

References (60)

1. UNAIDS (2012) Global report: UNAIDS report on the global AIDS epidemic 2012, Joint United Nations Programme on HIV/AIDS.
2. Fauci AS, (2003) HIV and AIDS: 20 years of science. Nat Med 9: 839-843.
3. De Clercq E, (2002) New developments in anti-HIV chemotherapy. Biochimica Et Biophysica Acta-Molecular Basis of Disease 1587: 258-275.
4. Zdanowicz MM, (2006) The pharmacology of HIV drug resistance. Am J Pharm Educ 70: 100.
5. Darbyshire J, (1995) Perspectives in drug therapy of HIV infection. Drugs 49 Suppl 1: 1-3 discussion 38-40.
6. Bean P, (2005) New drug targets for HIV. Clin Infect Dis 41 Suppl 1: 96-100.
7. Imamichi T, (2004) Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des 10: 4039-4053.
8. Hartman TL, Buckheit RW Jr, (2012) The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets. Mol Biol Int 2012: 401965.
9. Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, et al. (2008) Novel targets for HIV therapy. Antiviral Res 80: 251-265.
10. Martinez LJ, (2002) The need for novel targets and approaches to HIV therapy. Res Initiat Treat Action 8: 23-25.
11. Hang JQ, Li Y, Yang Y, Cammack N, Mirzadegan T, et al. (2007) Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem Biophys Res Commun 352: 341-350.
12. Julias JG, McWilliams MJ, Sarafianos SG, Alvord WG, Arnold E, et al. (2003) Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. J Virol 77: 8548-8554.
13. Sarafianos SG, Das K, Hughes SH, Arnold E, (2004) Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr Opin Struct Biol 14: 716-730.
14. Himmel DM, Maegley KA, Pauly TA, Bauman JD, Das K, et al. (2009) Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Structure 17: 1625-1635.
15. Lansdon EB, Liu Q, Leavitt SA, Balakrishnan M, Perry JK, et al. (2011) Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob Agents Chemother 55: 2905-2915.
16. Davies JF 2nd, Hostomska Z, Hostomsky Z, Jordan SR, Matthews DA, (1991) Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 252: 88-95.
17. Ilina T, Labarge K, Sarafianos SG, Ishima R, Parniak MA, (2012) Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. Biology (Basel) 1: 521-541.
18. Klumpp K, Mirzadegan T, (2006) Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr Pharm Des 12: 1909-1922.
19. Tramontano E, Di Santo R, (2010) HIV-1 RT-associated RNase H function inhibitors: Recent advances in drug development. Current Medicinal Chemistry 17: 2837-2853.
20. Felts AK, Labarge K, Bauman JD, Patel DV, Himmel DM, et al. (2011) Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies. J Chem Inf Model 51: 1986-1998.
21. Budihas SR, Gorshkova I, Gaidamakov S, Wamiru A, Bona MK, et al. (2005) Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res 33: 1249-1256.
22. Klumpp K, Hang JQ, Rajendran S, Yang Y, Derosier A, et al. (2003) Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res 31: 6852-6859.
23. Shaw-Reid CA, Munshi V, Graham P, Wolfe A, Witmer M, et al. (2003) Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem 278: 2777-2780.
24. Pubchem BioAssay Database. Available: http://www.pubchem.ncbi.nlm.nih.gov. Accessed 2013 Mar 20.
25. Han L, Wang Y, Bryant SH, (2008) Developing and validating predictive decision tree models from mining chemical structural fingerprints and high-throughput screening data in PubChem. BMC Bioinformatics 9: 401.
26. Distinto S, Esposito F, Kirchmair J, Cardia MC, Gaspari M, et al. (2012) Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. Eur J Med Chem 50: 216-229.
27. Vasanthanathan P, Lastdrager J, Oostenbrink C, Commandeur JNM, Vermeulen NPE, et al. (2011) Identification of CYP1A2 ligands by structure-based and ligand-based virtual screening. MedChemComm 2: 853-859.
28. Schneider G, Bohm HJ, (2002) Virtual screening and fast automated docking methods. Drug Discovery Today 7: 64-70.
29. McInnes C, (2007) Virtual screening strategies in drug discovery. Curr Opin Chem Biol 11: 494-502.
30. Billamboz M, Bailly F, Barreca ML, De Luca L, Mouscadet JF, et al. (2008) Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. J Med Chem 51: 7717-7730.
31. Billamboz M, Bailly F, Lion C, Touati N, Vezin H, et al. (2011) Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function. J Med Chem 54: 1812-1824.
32. Borkow G, Fletcher RS, Barnard J, Arion D, Motakis D, et al. (1997) Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry 36: 3179-3185.
33. Di Grandi M, Olson M, Prashad AS, Bebernitz G, Luckay A, et al. (2010) Small molecule inhibitors of HIV RT Ribonuclease H. Bioorg Med Chem Lett 20: 398-402.
34. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, et al. (2004) A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A 101: 11233-11238.
35. Kirschberg TA, Balakrishnan M, Squires NH, Barnes T, Brendza KM, et al. (2009) RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem 52: 5781-5784.
36. Su HP, Yan Y, Prasad GS, Smith RF, Daniels CL, et al. (2010) Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol 84: 7625-7633.
37. Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, et al. (2005) 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res 65: 117-124.
38. Wendeler M, Lee HF, Bermingham A, Miller JT, Chertov O, et al. (2008) Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity. ACS Chem Biol 3: 635-644.
39. Williams PD, Staas DD, Venkatraman S, Loughran HM, Ruzek RD, et al. (2010) Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold. Bioorg Med Chem Lett 20: 6754-6757.
40. Yanagita H, Urano E, Matsumoto K, Ichikawa R, Takaesu Y, et al. (2011) Structural and biochemical study on the inhibitory activity of derivatives of 5-nitro-furan-2-carboxylic acid for RNase H function of HIV-1 reverse transcriptase. Bioorg Med Chem 19: 816-825.
41. Parniak MA, Min KL, Budihas SR, Le Grice SF, Beutler JA, (2003) A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity. Anal Biochem 322: 33-39.
42. Standardizer (v5.12.2) (2013), ChemAxon. Available: http://www.chemaxon.com.
43. Hawkins PC, Skillman AG, Warren GL, Ellingson BA, Stahl MT, (2010) Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model 50: 572-584.
44. Michael RB, Nicolas C, Fabian D, Thomas RG, Tobias KO, et al. (2009) KNIME-The Konstanz Information Miner ACM SIGKDD Explorations Newsletter. New York, USA: ACM pp. 31.
45. Canvas (v1.5) (2012) Schrödinger, LLC, New York, NY.
46. Witten IH, Frank E (2005) Data Mining: Practical machine learning tools and techniques. San Francisco: Morgan Kaufmann.
47. Hall M, Frank E, Holmes H, Pfahringer B, Reutemann P, et al. (2009) The WEKA Data Mining Software: An Update. SIGKDD Explorations 11.
48. Yap CW, (2011) PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem 32: 1466-1474.
49. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, et al. (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20: 647-671.
50. Schrödinger Suite (2013) Schrödinger LLC., Portland, USA. Available: http://www.schrodinger.com.
51. vROC OEChem, (v1.7.2) (2010), OpenEye Scientific Software, Inc., Santa Fe, NM, USA. Available: http://www.eyesopen.com.
52. Grant JA, Gallardo MA, Pickup BT, (1996) A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape. J Comput Chem 17: 1653-1666.
53. Baroni M, Cruciani G, Sciabola S, Perruccio F, Mason JS, (2007) A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf Model 47: 279-294.
54. Arnold K, Bordoli L, Kopp J, Schwede T, (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22: 195-201.
55. Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W, (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27: 221-234.
56. Li H, Robertson AD, Jensen JH, (2005) Very fast empirical prediction and rationalization of protein pKa values. Proteins 61: 704-721.
57. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749.
58. Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, et al. (2007) Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 21: 681-691.
59. Didierjean J, Isel C, Querre F, Mouscadet JF, Aubertin AM, et al. (2005) Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob Agents Chemother 49: 4884-4894.
60. Singh N, Chaudhury S, Liu R, AbdulHameed MD, Tawa G, et al. (2012) QSAR classification model for antibacterial compounds and its use in virtual screening. J Chem Inf Model 52: 2559-2569.